Bio-Matrix Scientific Group, Inc. Outlines Strategy for Growth in 2010 With Focus on Developing Stem Cell Related Research and A
February 25 2010 - 8:00AM
Marketwired
Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) announced today its
growth strategy for 2010. The Company announced that it will apply
its resources toward conducting stem cell related research aimed at
developing and commercializing innovative new therapies. The
Company also announced its intent to actively pursue strategic
partnerships and acquisitions. BMSN is currently in various stages
of negotiation with several niche biotechnology companies regarding
joint ventures, alliances and business combinations which the
Company feels will diversify potential revenue streams.
An example of the strategic synergy being developed is the
recent progress made by Entest Biomedical, Inc. (OTCBB: ENTB), a
publicly traded subsidiary of the Company which is pioneering the
novel field of regenerative photoceuticals as applied to Chronic
Obstructive Pulmonary Disease (COPD), a condition afflicting an
estimated 24 million people. Last week Entest, in collaboration
with leading researchers, published a peer reviewed paper outlining
its ENT-576 therapeutic approach, which can be accessed at
http://www.translational-medicine.com/content/pdf/1479-5876-8-16.pdf.
David Koos, the Company's Chairman & CEO, stated, "We have
invested substantial efforts into developing clinical-grade cell
processing procedures, protocols, and facilities. As a result of
these efforts, we feel our 15,000 square foot facility is state of
the art. We are now seeking to expand the use of these assets
beyond conventional stem cell storage, which previously had been
our core business. There are a number of potential relationships
forming with companies which present unique opportunities that can
be advantageous to our overall goal of establishing Bio-Matrix as a
world leader in stem cell therapeutics."
A spokesperson for Bio-Matrix Scientific Group noted that
further details will be discussed on the Company's Shareholder
Conference Call slated for March 23, 2010. Those wishing to
participate in the call are requested to email or fax their name,
email address and any questions they wish addressed during the call
to info@bmsn.us (email) or 619.330.2328(fax) prior to March 10,
2010. Instructions, including call in number and access codes, will
be emailed to participants once details have been finalized.
About Bio-Matrix Scientific Group:
Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a
biotechnology company headquartered in San Diego, Ca. with a 15,000
sq. ft. facility that houses two secure cryogenic stem cell banks,
three research laboratories, aseptic cellular/tissue class
10,000/100 processing lab, hematology, microbiology and flow
cytometry laboratories. David Koos serves as Chairman & CEO
concurrently for BMSN and ENTB. Entest Biomedical, Inc. (OTCBB:
ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group
Inc. (OTCBB: BMSN).
Forward-looking statements
This news release may contain forward-looking statements.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition and other material risks.
Contact: David R. Koos Chairman & CEO Bio-Matrix Scientific
Group Inc. 619.702.1404 Direct 619.330.2328 Fax www.BMSN.us Email
Contact